Bristol-Myers Squibb
BMS-986278
Idiopathic Pulmonary Fibrosis
Countdown
92days
Phase 3 readout · Oct 6, 2026
What's at stake
Phase 3 trial results for BMS-986278 in Idiopathic Pulmonary Fibrosis are due Oct 6, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT06003426: Phase 3 trial, sponsor Bristol-Myers Squibb, drug BMS-986278. Primary completion date 2026-10-06 (estimated).”